STOCK TITAN
  1. Home
  2. News
  3. ATRA

Atara Biotherapeutics Inc - ATRA STOCK NEWS

Welcome to our dedicated news page for Atara Biotherapeutics (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atara Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atara Biotherapeutics's position in the market.

News
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. The data supports ATA3431's advancement into clinical testing for the treatment of B-cell malignancies, with promising results compared to an autologous CAR-T benchmark. The company is excited about the potential of ATA3431 and looks forward to evaluating it in the clinic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
clinical trial
-
News
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) reported the grant of 27,000 restricted stock units to three new employees under the 2018 Inducement Plan. The units vest over four years, subject to continuous employment. This move aims to attract and retain talent, aligning employee interests with company growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
Rhea-AI Summary
Atara Biotherapeutics, a leader in T-cell immunotherapy, announced positive data for tabelecleucel (tab-cel® or EBVALLO™) in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system. The multicohort Phase 2 EBVision trial showed a 77.8% objective response rate in 18 patients, with a favorable safety profile. The estimated one-year overall survival rate was 70.6% for all patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
conferences clinical trial
News
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) to participate in fireside chat at Evercore ISI HealthCONx Conference. Pascal Touchon, President and CEO, to present at 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023, at 10:50 a.m. EST. Webcast available on atarabio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at Stifel Healthcare Conference on November 14, 2023, discussing T-cell immunotherapy and EBV T-cell platform. Pascal Touchon, President and CEO, to participate in a fireside chat at 8:30 a.m. PST / 11:30 a.m. EST. Webcast available on atarabio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announces the disappointing results of its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS), failing to meet the primary endpoint of confirmed disability improvement (CDI). Despite this setback, the company remains optimistic about its allogeneic CAR-T portfolio and plans to focus resources on advancing this pipeline, while also reducing expenses and extending its cash runway beyond Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-80.17%
Tags
clinical trial
News
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Rhea-AI Summary
Atara Biotherapeutics reports expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel®), financial results for Q3 2023, and upcoming catalysts. The partnership includes up to $640 million in payments, double-digit tiered royalties, and funding of tab-cel global development costs. Atara is restructuring to reduce expenses and extend cash runway. ATA188 Phase 2 EMBOLD study analysis on track for early November. Atara will focus on ATA188 and allogeneic CAR-T programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
partnership earnings
-
News
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Atara Biotherapeutics reports grant of restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
Rhea-AI Summary
Atara Biotherapeutics reports progress in regulatory pathway for tabelecleucel, expects to submit BLA in Q2 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
earnings
News
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Atara Biotherapeutics grants 3,250 restricted stock units to a newly hired employee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock ATRA logo
Atara Biotherapeutics Inc

Nasdaq:ATRA

ATRA Rankings

#4393 Ranked by Market Cap
#5201 Ranked by Stock Gains
N/A Ranked by Dividends

ATRA Stock Data

81.36M
90.37M
5.9%
62.91%
9.41%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
South San Francisco

About ATRA

we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have